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Background
Facial soft tissue augmentation and rejuvenation have
become over the past several years the practice more
requested in aesthetic medicine. The authors share their
experiences to evaluate long term safety, clinical effec-
tiveness and patient satisfaction regarding the injection
of hyaluronic acid (HA) filler and botulinum toxyn tipe
A (BTTA). In some cases the patient received a com-
bined treatment of HA and BTTA to obtain absolute
aestethic satisfaction.
Materials and methods
From June 2007 to June 2009, a total of 208 caucasian
patients (179 female and 29 male) received a HA or
BTTA or combined (63 cases) injection in differents
facial areas: oral commissure, nasolabial folds 1, lips,
cheeks, chin. Formulations used in this study are the
20mg/mL HA smooth, highly cohesive, viscous, fully
reversible, volumizing filler 2 indicated to restore facial
volume and 50 units of Clostridium botulinum type A
neurotoxin complex, added with 1,0 mL of saline solu-
tion 0,9%. This trial has been structured with a preli-
minary visit to evaluate the loss of volume and the
individual expectations. All injections of HA were in the
deep dermis or above the periosteum whereas BTTA
were performed in intramuscular site in frontal, orbito-
zygomatic regions and in glabellar area. The most part
of injections were not performed under local anesthesia
and the mean total of injection volume per each patient
was about 4.4 mL for HA and 1,0 mL for BTTA 3.
Every patient was photographed at each visit, before and
after the treatment with a follow up at 7, 14, 21 and 45
days, recording procedural details, effectiveness, aes-
thetic outcomes and adverse events. Patients were also
asked to evaluate their personal satisfaction by using a
subjective scale from 0 (no satisfaction) to 5 (absolute
satisfaction) starting from pre treatment photos. Finally
they were asked if they would repeat the treatment
again.
Results
Volume loss declined significatly after treatment and
every patient noted a positive change in his own appear-
ance. Local adverse events appeared only in three
patients: two of those consisting in a local transitory
edema and inflammatory reaction and the third was a
slight blepharoptosis for BTTA, normalized one month
later.. Personal satisfaciotn has been absolute in 182
patients (87.5%) and 98% of the patients would repeat
treatment.
Conclusions
The 20-mg/mL smooth, highly cohesive, viscous, volu-
mizing HA filler and the BTTA were effective, well
tolerated and easy to use in clinical practice.
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